Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2019.230805
Abstract: by Andrew R. Pettitt, Richard Jackson, Silvia Cicconi, Fotis Polydoros, Christina Yap, James Dodd, Matthew Bickerstaff, Michael Stackpoole, Umair T. Khan, Stacey Carruthers, Melanie Oates, Ke Lin, Sarah E. Coupland, Geetha Menon, Nagesh Kalakonda, Helen… read more here.
Keywords: dexamethasone alemtuzumab; high risk; ofatumumab high; risk chronic ... See more keywords